Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. OMER
stocks logo

OMER

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
--
--
-0.545
-51.34%
--
--
-0.477
-25.39%
--
--
0.163
-129.55%
Estimates Revision
The market is revising No Change the revenue expectations for Omeros Corporation (OMER) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 164.51%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-38.07%
In Past 3 Month
Stock Price
Go Up
up Image
+164.51%
In Past 3 Month
Wall Street analysts forecast OMER stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OMER is 13.11 USD with a low forecast of 6.22 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast OMER stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OMER is 13.11 USD with a low forecast of 6.22 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 11.030
sliders
Low
6.22
Averages
13.11
High
20.00
Current: 11.030
sliders
Low
6.22
Averages
13.11
High
20.00
H.C. Wainwright
Brandon Folkes
Buy
maintain
$9
2025-06-27
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$9
2025-06-27
maintain
Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$36
2025-04-11
Reason
D. Boral Capital
Jason Kolbert
Price Target
$36
2025-04-11
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$36
2025-04-01
Reason
D. Boral Capital
Jason Kolbert
Price Target
$36
2025-04-01
Maintains
Strong Buy
Reason
Needham
Serge Belanger
Hold
Reiterates
n/a
2025-04-01
Reason
Needham
Serge Belanger
Price Target
n/a
2025-04-01
Reiterates
Hold
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$36
2025-03-21
Reason
D. Boral Capital
Jason Kolbert
Price Target
$36
2025-03-21
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$36
2025-02-20
Reason
D. Boral Capital
Jason Kolbert
Price Target
$36
2025-02-20
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Omeros Corp (OMER.O) is -38.70, compared to its 5-year average forward P/E of -4.55. For a more detailed relative valuation and DCF analysis to assess Omeros Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.55
Current PE
-38.70
Overvalued PE
1.09
Undervalued PE
-10.19

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
156.59
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
857.25
Undervalued EV/EBITDA
-544.07

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
26.52
Current PS
0.00
Overvalued PS
59.95
Undervalued PS
-6.91
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 185085.19% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

OMER News & Events

Events Timeline

(ET)
2025-11-13
16:12:43
Omeros announces Q3 adjusted EPS of 34 cents, falling short of consensus estimate of 48 cents.
select
2025-10-16 (ET)
2025-10-16
09:29:08
Omeros Reveals Survival Benefits of Narsoplimab in TA-TMA Publication
select
2025-10-15 (ET)
2025-10-15
10:53:11
H.C. Wainwright Increases Omeros Price Target from $9 to $20
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
12-04Benzinga
Snowflake, Symbotic, and Other Major Stocks Decline in Thursday's Pre-Market Trading

  • U.S. Stock Futures: U.S. stock futures showed mixed results, with Dow futures up by approximately 0.1% on Thursday morning.

  • Snowflake Inc Performance: Snowflake Inc reported third-quarter revenue of $1.21 billion, surpassing analyst expectations, but its shares fell 8.6% in pre-market trading.

  • Other Stocks Declining: Several other stocks experienced significant declines in pre-market trading, including Net Lease Office Properties down 14.7% and Symbotic Inc down 10.5% following a share offering announcement.

  • Additional Stock Movements: Other notable declines included Capricor Therapeutics down 8.4% after a previous surge, and ADC Therapeutics down 8.1% after reporting trial data.

[object Object]
Preview
4.0
12-02Benzinga
D. Boral Capital Reiterates Buy Rating on Omeros with $36 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.

[object Object]
Preview
8.5
12-01Yahoo Finance
Omeros Finalizes Asset Acquisition and Licensing Agreement with Novo Nordisk for Zaltenibart

  • Asset Sale Completion: Omeros (OMER) has successfully closed a deal involving the sale and licensing of its assets to another company.

  • Strategic Move: This transaction is part of Omeros' strategy to enhance its financial position and focus on core operations.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Omeros Corp (OMER) stock price today?

The current price of OMER is 11.03 USD — it has increased 3.86 % in the last trading day.

arrow icon

What is Omeros Corp (OMER)'s business?

Omeros Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan diseases, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The Company's lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before the FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. Its lead phosphodiesterase 7 (PDE7) inhibitor, OMS527, is in clinical development for the treatment of cocaine use disorders. The Company also has preclinical programs, including an oncology platform for the development of novel therapeutics.

arrow icon

What is the price predicton of OMER Stock?

Wall Street analysts forecast OMER stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OMER is 13.11 USD with a low forecast of 6.22 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Omeros Corp (OMER)'s revenue for the last quarter?

Omeros Corp revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Omeros Corp (OMER)'s earnings per share (EPS) for the last quarter?

Omeros Corp. EPS for the last quarter amounts to -0.47 USD, decreased -16.07 % YoY.

arrow icon

What changes have occurred in the market's expectations for Omeros Corp (OMER)'s fundamentals?

The market is revising No Change the revenue expectations for Omeros Corporation (OMER) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 164.51%.
arrow icon

How many employees does Omeros Corp (OMER). have?

Omeros Corp (OMER) has 202 emplpoyees as of December 05 2025.

arrow icon

What is Omeros Corp (OMER) market cap?

Today OMER has the market capitalization of 782.03M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free